연구동향 분석

Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy

허미화 김희경 이한상 김지연 안진석 임영혁 박연희 2019년

논문상세정보
인용/피인용
' Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Breast neoplasms
  • Female
  • fulvestrant
  • postmenopause
  • salvage therapy
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
505 0

0.0%

' Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy' 의 참고문헌

  • Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
    Fry DW [2004]
  • Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer
  • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
  • Nation-Wide Korean Breast Cancer Data from 2008 Using the Breast Cancer Registration Program
    정용식 [2011]
  • Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women : a prospective combined analysis of two multicenter trials
  • Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma : a prospectively planned combined survival analysis of two multicenter trials
    Howell A [2005]
  • Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy(PALOMA-3) : final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
  • Fulves-trant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
    Howell A [2002]
  • Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial
    Di Leo A [2014]
  • FDA approval of palbociclib in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer
    Walker AJ [2016]
  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer(ABC2)
    Cardoso F [2014]
  • Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer : results from EFECT
    Chia S [2008]
  • Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
    Toogood PL [2005]
  • Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy : a multinational, double-blind, randomized trial
    Howell A [2004]
  • A potent specific pure antiestrogen with clinical potential
    Wakeling AE [1991]